STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3615 by analyst upside · 2026-08-12
LH
Labcorp Holdings Inc.
Healthcare · Market Cap $26B · P/E 26.7x
ANALYST PRICE TARGET
+4.8%
implied upside to consensus target
Current Price $322.42
Consensus Target $337.75
Bull Target $385.0
Bear Target $270.0
Analysts Covering 16
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
10
Hold
4
Sell
0
52-Week Low $244.52
52-Week High $323.97
YTD Return +28.8%
FUNDAMENTALS
Market Cap $26B
P/E Ratio (TTM) 26.7x
Forward P/E 16.3x
EPS (TTM) $12.08
PEG Ratio 1.34
Dividend Yield 0.90%
Revenue (TTM) $14.3B
Profit Margin 7.0%
52-WEEK RANGE
52-Week Low $244.52
52-Week High $323.97
Current Price $322.42
Bear Target $270.0
Bull Target $385.0
● Now $322.42 ● Target $337.75
TRADING DATA
Avg Volume 672K
YTD Return +28.8%
Analyst Count 16
Consensus Buy
Upside to Target +4.8%
Last Updated 2026-08-12

ANALYST SUMMARY

Labcorp Holdings Inc. (LH) is currently trading at $322.42 with a Wall Street consensus price target of $337.75, implying potential upside of 4.8% over the next 12 months. 16 analysts currently cover LH, with a consensus rating of Buy - 75% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $385.0, while the most cautious has a target of $270.0.

LH operates in the Healthcare sector with a market capitalisation of $26B. The stock is up 28.8% year-to-date and is currently trading near the upper end of its 52-week range of $244.52 – $323.97.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for LH, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Evercore ISI Group - Reiterated
Outperform → Outperform 2026-04-08 Building track record
Piper Sandler - Reiterated
Neutral → Neutral 2026-02-24 14% win rate (7 calls)
JP Morgan - Reiterated
Overweight → Overweight 2026-02-18 43% win rate (7 calls)
Baird - Reiterated
Outperform → Outperform 2026-02-18 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-02-06 43% win rate (7 calls)
JP Morgan - Reiterated
Overweight → Overweight 2025-11-07 43% win rate (7 calls)
UBS - Reiterated
Buy → Buy 2025-10-29 33% win rate (6 calls)
UBS - Reiterated
Buy → Buy 2025-10-17 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
59
out of 100
Coverage depth
22/30
Consensus clarity
23/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →